Equities

GuangYuYuan Chinese Herbal Medicine Co Ltd

600771:SHH

GuangYuYuan Chinese Herbal Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.56
  • Today's Change-0.22 / -0.93%
  • Shares traded4.55m
  • 1 Year change-38.77%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GuangYuYuan Chinese Herbal Medicine Co., Ltd. is a China-based company principally engaged in the manufacture and sale of traditional Chinese medicine and health wine. The Company's products types consist of traditional Chinese medicine, fine Chinese medicine and health wine, which include Dingkun Dan, Guilingji, Angong Niuhuang Pills and Niuhuang Qingxin Pills, among others. The Company distributes its products in domestic market.

  • Revenue in CNY (TTM)1.26bn
  • Net income in CNY121.59m
  • Incorporated1996
  • Employees1.81k
  • Location
    GuangYuYuan Chinese Herbal Medicine Co Ltd6F, Tower A, Liren Technology ParkNo. 52 High-Tech RoadHigh-Tech ZoneTAIYUAN 030000ChinaCHN
  • Phone+86 3 517099061
  • Fax+86 3 517099130
  • Websitehttps://www.guangyuyuan.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NanJing Pharmaceutical Co Ltd53.46bn587.75m6.25bn4.90k10.570.9378--0.11690.45130.451341.075.091.638.333.3310,903,610.002.222.327.448.946.046.411.361.301.132.910.635929.826.7111.35-3.0016.93-12.679.86
Guangxi LiuYao Group Co Ltd21.25bn888.87m8.75bn5.58k8.921.15--0.4122.462.4658.8219.121.076.991.973,807,204.004.805.0611.7312.2111.5611.854.474.401.305.260.543429.909.2312.1821.119.97-8.636.26
GuangYuYuan Chinese Herbal Medicn Co Ltd1.26bn121.59m11.64bn1.81k95.737.57--9.250.24840.24842.573.140.47010.76611.99694,836.904.96-2.107.42-3.1671.4369.7410.56-6.001.1612.910.1569--13.56-4.53136.03-24.78-58.35--
Tibet Rhodiola Pharmaceutical Holding Co2.93bn810.63m11.93bn601.0013.182.51--4.072.812.819.6514.760.60161.816.684,877,892.0016.8312.4423.1815.7193.6890.5127.9720.432.797.960.171650.4122.6924.98116.5630.01-1.4848.97
China Meheco Group Co Ltd35.07bn924.87m16.23bn8.39k17.551.39--0.46280.61830.618323.447.830.92244.582.284,180,309.002.963.406.727.7611.2214.153.212.931.228.890.33528.223.284.6042.45-7.466.72-1.02
Data as of May 24 2024. Currency figures normalised to GuangYuYuan Chinese Herbal Medicine Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.68%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 31 Dec 20232.38m0.48%
China Universal Asset Management Co., Ltd.as of 31 Dec 20232.21m0.45%
Yinhua Fund Management Co., Ltd.as of 31 Dec 20231.49m0.30%
China Merchants Fund Management Co., Ltd.as of 31 Dec 20231.34m0.27%
CCB Principal Asset Management Co., Ltd.as of 31 Dec 20231.34m0.27%
The Vanguard Group, Inc.as of 09 May 20241.30m0.26%
China Asset Management Co., Ltd.as of 31 Dec 20231.16m0.24%
Penghua Fund Management Co., Ltd.as of 30 Jun 2023969.62k0.20%
Changsheng Fund Management Co., Ltd.as of 31 Dec 2023590.00k0.12%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023419.22k0.09%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.